PlainPharmaWatch

CMS Open Payments · Tool

Gilead Sciences, Inc. vs Servier BioInnovation

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Servier BioInnovation has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 2,211, versus 168 for the other company. Its single largest recorded recipient represents 40.7% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Gilead Sciences, Inc.
HHI 168 · top recipient 10.8%
Ranked #1,596 of 1,838 companies by HHI
Servier BioInnovation
HHI 2,211 · top recipient 40.7%
Ranked #715 of 1,838 companies by HHI

Payment Overview

Total Payments
$72.7M
% of Industry
0.5%
Transactions
121,377
Avg per Transaction
$598.70
Recipients
118,932
Avg per Recipient
$611.01
Payment Types
8
Top Payment Type
Grant
Total Payments
$83.4M
% of Industry
0.6%
Transactions
4,040
Avg per Transaction
$20.6K
Recipients
11
Avg per Recipient
$7.6M
Payment Types
2
Top Payment Type
Food and Beverage

Highlighted values indicate the higher figure for each metric.

Total payments compared

Gilead Sciences, Inc. vs Servier BioInnovation - total reported payments in CMS Open Payments PY2024

Servier BioInnovation$83.4MGilead Sciences, Inc.$72.7M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Gilead Sciences, Inc.

Grant $15.7M

39.7%

Compensation for Services Other Than Consulting $10.6M

26.8%

Consulting Fee $5.4M

13.6%

Food and Beverage $3.6M

9.1%

Travel and Lodging $2.5M

6.4%

Royalty or License $1.1M

2.9%

Servier BioInnovation

Food and Beverage $1.4K

68.8%

Travel and Lodging $642.11

31.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Gilead Sciences, Inc.

  1. 1

    Emory University Hospital

    $4,269,910.88 · 21 txns

  2. 2

    Ochsner Clinic Foundation

    $1,465,691.70 · 25 txns

  3. 3

    University Of Washington Med Ctr

    $1,201,838.91 · 17 txns

  4. 4

    Ph Patewood Hospital

    $701,326.00 · 6 txns

  5. 5

    Hackensack University Medical Center

    $613,813.00 · 6 txns

Servier BioInnovation

  1. 1

    STACEY JOY SIMMONS

    $839.45 · 4 txns

  2. 2

    ROBERT ARTHUR CHONG

    $196.85 · 1 txns

  3. 3

    TIMOTHY CLOUGHESY

    $196.85 · 1 txns

  4. 4

    PATRICK WEN

    $196.85 · 1 txns

  5. 5

    INGO MELLINGHOFF

    $196.85 · 1 txns

Summary Comparison

Metric Gilead Sciences, Inc. Servier BioInnovation
Total Payments $72.7M $83.4M
% of Industry Total 0.5% 0.6%
Transaction Count 121,377 4,040
Avg per Transaction $598.70 $20.6K
Recipient Count 118,932 11
Avg per Recipient $611.01 $7.6M
Payment Type Count 8 2
Top Payment Type Grant Food and Beverage

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.